






▶ Les anti-agrégants

**PRESCRIRE SANS
NUIRE**



To treat or not to treat?





Risque cardio-vasculaire

- ▶ **Décès**
- ▶ **Infarctus myocardique**
- ▶ **AVC**
- ▶ **Ischémie distale**



Risque hémorragique

- ▶ **Saignements fatals**
- ▶ **Saignements majeurs dont les hémorragies intracrâniennes**
- ▶ **Saignements digestifs: hauts et bas**
- ▶ **autres saignements**



Que disent les recommandations ?

▶ **Prévention primaire :**

Aucune indication dans la prévention coronaire


Seule indication de l'artériopathie des m inf

Que disent les recommandations ?

▶ **Prévention secondaire :**

- Prévention récurrence infarctus myocardique
- Prévention risque AVC -AIT
- Prévention artériopathie périphérique
- Syndrome des anti-phospholipides avec perte foetale
- Pré-éclampsie


Algorithm for dual antiplatelet therapy (DAPT) in patients treated with percutaneous coronary intervention



Que disent les recommandations ?

► Prévention secondaire :

Si PAC avec haut risque de saignement : arrêter l'inhibiteur PY12 après 6 mois



Que disent les recommandations ?

▶ **Prévention secondaire :**

Utilisation libérale des IPP pour réduire les risques de hémorragies digestives hautes (1B)

Que disent les recommandations ?

- ▶ **Aspirine: indication prévention secondaire long terme SCA , artériopathie périphérique et AVC hors FA**
- ▶ **Clopidogrel: en association avec ASA dans le SCA ou à la place de l'aspirine en cas d'allergie**
Variabilité dans la réponse (résistance ou hyper-répondeur déterminé génétiquement)

Molécules disponibles :

▶ **Prasugrel : seulement en cas de stent chez un STEMI diabétique et jeune ou cas de thrombose de stent**

Pas de résistance biologique

▶ **Ticagrelor : dans le SCA , PCI,**

Mais attention dyspnée, CI : hémorragie intracrânienne, haut risque de saignement

Risk scores validated for dual antiplatelet therapy duration decision-making

	PRECISE-DAPT score	DAPT score	
Time of use	At the time of coronary stenting	After 12 months of an eventful DAPT	
DAPT duration strategies assessed	Short DAPT (3–6 months) vs. Standard/long DAPT (12–24 months)	Standard DAPT (12 months) vs. Long DAPT (30 months)	
Score calculation	<p>HB ≥ 2 11-5 11 10-5 ≤ 10</p> <p>WBC ≤ 5 8 10 12 14 16 18 ≥ 20</p> <p>Age ≤ 50 60 70 80 ≥ 90</p> <p>CrCl ≥ 100 80 60 40 20 0</p> <p>Prior Bleeding No _____ Yes</p> <p>Score Points 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30</p>	<p>Age ≥ 75 -2 pt</p> <p>65 to <75 -1 pt</p> <p><65 0 pt</p> <p>Cigarette smoking +1 pt</p> <p>Diabetes mellitus +1 pt</p> <p>MI at presentation +1 pt</p> <p>Prior PCI or prior MI +1 pt</p> <p>Paclitaxel-eluting stent +1 pt</p> <p>Stent diameter <3 mm +1 pt</p> <p>CHF or LVEF <30% +2 pt</p> <p>Vein graft stent +2 pt</p>	
Score range	0 to 100 points	-2 to 10 points	
Decision making cut-off suggested	Score ≥ 25 → Short DAPT Score <25 → Standard/long DAPT	Score ≥ 2 → Long DAPT Score <2 → Standard DAPT	
Calculator	www.precisedaptscore.com	www.daptstudy.org	

Haemoglobin ?

unit

g/dl

mmol/L

Age (years)

White blood cells ?

unit

u/mcL


10⁹/L

Creatinine Clearance (ml/min) ?

Prior Bleeding ?

CALCULATE

RESET



RESULT:

Cluster of risk:

Score Calculated

12 months risk of TIMI
major or minor
Bleeding

12 months risk of TIMI
Major Bleeding

Copy to clipboard

Les antiagrégants

DAPT calculator

The screenshot shows a web browser window displaying the DAPT Risk Calculator. The browser's address bar shows the URL <https://tools.acc.org/DAPTriskapp/#!/content>. The page header includes the American College of Cardiology logo and the text "DAPT Risk Calculator". There are two main navigation buttons: "Calculator" (highlighted in blue) and "Complete Results".

The main content area displays the message "DAPT Score: Not Enough information". Below this is an informational box with the text: "The DAPT Score was created in patients who had completed 12 months of DAPT without having a major bleeding or ischemic event and who were not on chronic oral anticoagulation. The DAPT Risk Calculator is recommended to be used for guidance in the overall conversation about dual antiplatelet therapy and not as a recommendation for or against any medical treatment." A close button (X) is located in the top right corner of this box.

The "DAPT Risk Calculator" title is followed by a "Reset" button. The "Patient Characteristics" section includes an "Age" input field with a "Years" label and a note "Must be between 18-100". Below this is a "Select all that apply" section with several conditions, each with an unselected toggle switch:

- Diabetes Mellitus
- Prior Myocardial Infarction or Percutaneous Coronary Intervention
- Hypertension ⓘ
- Peripheral Arterial Disease ⓘ
- Cigarette Smoking Within Last Two Years
- History of Congestive Heart Failure or Left Ventricular Ejection Fraction < 30%
- Renal Insufficiency ⓘ


The "Procedure Characteristics" section is partially visible at the bottom of the page.

Les antiagrégants

Prescrire sans nuire

https://tools.acc.org/DAPTiskapp/#/content | clinical.med-iq.com | DAPT Risk Calculator

Laboratoire Synlab Belgiu... | Accueil - INAMI | Centre Belge d'Informatio... | Consultation - Cyberl@b ... | ESTEL NET | Google Agenda | Intranet CHC | Laboratoire Olivier | Outlook Web App

 AMERICAN COLLEGE of CARDIOLOGY | DAPT Risk Calculator

Calculator Complete Results

DAPT Score: Not Enough Information

Years
Must be between 18-100

Select all that apply

<input type="checkbox"/> Diabetes Mellitus	<input type="checkbox"/> Cigarette Smoking Within Last Two Years
<input type="checkbox"/> Prior Myocardial Infarction or Percutaneous Coronary Intervention	<input type="checkbox"/> History of Congestive Heart Failure or Left Ventricular Ejection Fraction < 30%
<input type="checkbox"/> Hypertension ⓘ	<input type="checkbox"/> Renal Insufficiency ⓘ
<input type="checkbox"/> Peripheral Arterial Disease ⓘ	

Procedure Characteristics

Select all that apply

<input type="checkbox"/> Myocardial Infarction at Presentation	<input type="checkbox"/> Stenting of Vein of Graft
<input type="checkbox"/> Stent Diameter < 3mm	




DAPT Risk Calculator

Calculator

Complete Results


DAPT Score: Not Enough information

Risk if DAPT Continued ⓘ



*Major Adverse Cardiovascular and Cerebrovascular Events


Risk if DAPT Discontinued ⓘ



*Major Adverse Cardiovascular and Cerebrovascular Events

Change in Risk

Risk difference of continued treatment with DAPT at 12-30 months minus discontinued treatment at 12-30 months.



*Major Adverse Cardiovascular and Cerebrovascular Events

en cas de triple thérapie :

- ▶ **La plus courte toujours ,**
- ▶ **l'inhibiteur PY12 sera toujours le clopidogrel**
- ▶ **et on laisse le NOAC ou l' AVK seul à 12 mois**

Averroes : quand l'aspirine est battue par un

- Apixaban significantly reduced risk of stroke or systemic embolic events by 54%
- The trial was stopped early when the data and safety monitoring board performed a prespecified interim analysis showing significant benefit with apixaban

Primary and secondary end points

Outcomes	Apixaban (n=2809), %	Aspirin (n=2791), %	Relative risk (95% CI)
Primary end point	1.6	3.6	0.46 (0.33–0.64)
Stroke, embolic event, MI, or vascular death	4.1	6.2	0.66 (0.53–0.83)
- MI	0.7	0.8	0.85 (0.48–1.50)
- Vascular death	2.5	2.9	0.86 (0.64–1.16)
CV hospitalization	11.8	14.9	0.79 (0.68–0.91)
Total death	3.4	4.4	0.79 (0.62–1.02)


En cas d'intolérance , instabilité ou effets secondaires d'un avk dans le prévention des AVC en FA

Risque AVC et Embol systémique

A


Age <75 years

Hazard ratio with apixaban, 0.68
(95% CI, 0.42-1.08)



Age ≥75 years

Hazard ratio with apixaban, 0.33
(95% CI, 0.19-0.54)



No. at Risk

	0	3	6	9	12	15	18
Aspirin	1799	1766	1643	1384	1009	675	402
Apixaban	1901	1869	1745	1455	1037	722	419

No. at Risk

	0	3	6	9	12	15	18
Aspirin	992	951	885	730	536	375	229
Apixaban	906	887	820	651	479	327	196


Risque hémorragique

Averroes

B

Age <75 years


Hazard ratio with apixaban, 1.14
(95% CI, 0.58-2.30)



No. at Risk	0	3	6	9	12	15	18
Aspirin	1799	1776	1654	1397	1019	682	407
Apixaban	1901	1872	1748	1455	1040	724	424

Age ≥75 years

Hazard ratio with apixaban, 1.21
(95% CI, 0.69-2.12)



No. at Risk	0	3	6	9	12	15	18
Aspirin	992	960	896	740	548	382	233
Apixaban	906	885	816	645	474	321	195



Merci pour votre attention